EntryPoint Capital’s Zevra Therapeutics ZVRA Stock Holding History

EntryPoint Capital’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$562K	Sell	39,176 -3,709	-9%	-$41.2K	0.14%	279
2026 Q1	$400K	Sell	42,885 -9,986	-19%	-$90K	0.12%	345
2025 Q4	$474K	Buy	52,871 +23,989	+83%	+$227K	0.18%	187
2025 Q3	$275K	Buy	+28,882	New	+$290K	0.11%	401
2025 Q2	–	Sell	-40,675	Closed	-$305K	–	848
2025 Q1	$305K	Buy	40,675 +14,225	+54%	+$113K	0.14%	316
2024 Q4	$221K	Buy	+26,450	New	+$226K	0.09%	551

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EntryPoint Capital's ZVRA Position: Q2 2026 in Review

EntryPoint Capital reduced its Zevra Therapeutics (ZVRA) stake by 8.6% in Q2 2026, selling an estimated $41.2K and leaving 39,176 shares worth $562K. The position accounts for 0.14% of the portfolio, ranked #279.

EntryPoint Capital first reported a position in ZVRA in Q4 2024 and has held it in 6 quarters since. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

EntryPoint Capital held 39,176 shares of Zevra Therapeutics worth $562K as of Q2 2026.
EntryPoint Capital sold 3,709 Zevra Therapeutics shares in Q2 2026, an estimated $41.2K.
Zevra Therapeutics made up 0.14% of EntryPoint Capital's portfolio in Q2 2026, its #279 holding.
EntryPoint Capital first reported a position in Zevra Therapeutics in Q4 2024 and has held it in 6 quarters since.
158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.